OBJECTIVES This study evaluated the effectiveness of hydrogen peroxide (H 2 O 2 ) as mouthwash and nasal spray on symptom relief in coronavirus disease 2019 (COVID-19) patients. METHODS Patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), who were treated in a hospital or at home, and patients’ family members (not positive for SARS-CoV-2), were randomized into 2 groups: experimental (1% H 2 O 2 for gargling, 0.5% H 2 O 2 for nasal wash), and control. Patients gargled the solution 3 times a day, and applied the nasal spray twice a day, for a 7-day period. Family members received the same treatment as the treated COVID-19 patient. The researchers contacted patients every 2 days over an 8-day period. An average post-treatment interval of 8 days passed before testing family members. RESULTS The most frequent symptoms on day 0 were cough, loss of taste, and hyposmia; there were no significant differences between groups, independent of the period. The symptom of dyspnea presented a significant difference between days 2 and 4 (p<0.05). Among family members, 86.0% had no antibodies, 2.3% had antibodies, and 11.6% had active infections (4 in the experimental group and 6 in the control group). The most frequent adverse effects in the H 2 O 2 group were a burning throat and nose. CONCLUSIONS H 2 O 2 was not effective for the relief of COVID-19 symptoms and was associated with reports of transient adverse effects.
【저자키워드】 COVID-19, Brazil, SARS-CoV-2, hydrogen peroxide, 【초록키워드】 Treatment, coronavirus disease, antibodies, coronavirus, hospital, nasal, Symptom, cough, Randomized, Dyspnea, Patient, Effectiveness, patients, COVID-19 patient, COVID-19 symptom, family member, adverse effect, acute respiratory syndrome, significant difference, control group, no significant difference, experimental group, average, loss of taste, positive, researcher, Effects, effective, independent, active infection, evaluated, applied, treated, had no, groups, transient adverse, 【제목키워드】 clinical trial, Randomized, double-blind, hydrogen, auxiliary, treatment for COVID-19,